Analyst Price Targets — ZTS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 26, 2026 11:08 am | Mark Massaro | BTIG | $160.00 | $128.95 | StreetInsider | BTIG Reiterates Buy Rating on Zoetis Inc. (ZTS) |
| January 29, 2026 2:22 pm | — | UBS | $136.00 | $122.75 | TheFly | Zoetis price target lowered to $136 from $141 at UBS |
| January 22, 2026 8:42 am | David Westenberg | Piper Sandler | $135.00 | $125.08 | StreetInsider | Piper Sandler Downgrades Zoetis Inc. (ZTS) to Neutral |
| December 18, 2025 12:56 pm | — | Morgan Stanley | $160.00 | $124.54 | TheFly | Zoetis price target lowered to $160 from $175 at Morgan Stanley |
| December 10, 2025 11:18 am | — | HSBC | $140.00 | $115.75 | TheFly | Zoetis price target lowered to $140 from $180 at HSBC |
| December 8, 2025 9:28 pm | — | Barclays | $136.00 | $118.16 | TheFly | Zoetis initiated with an Equal Weight at Barclays |
| November 4, 2025 6:05 pm | — | Stifel Nicolaus | $140.00 | $125.50 | TheFly | Zoetis price target lowered to $140 from $155 at Stifel |
| October 20, 2025 1:36 pm | — | UBS | $158.00 | $144.90 | TheFly | Zoetis price target lowered to $158 from $165 at UBS |
| August 11, 2025 10:29 am | David Westenberg | Piper Sandler | $215.00 | $148.86 | TheFly | Zoetis price target raised to $215 from $210 at Piper Sandler |
| June 17, 2025 10:44 pm | Jonathan Block | Stifel Nicolaus | $160.00 | $161.67 | TheFly | Zoetis downgraded to Hold from Buy at Stifel |
Latest News for ZTS
Berkeley Inc cut its stake in shares of Zoetis Inc. (NYSE: ZTS) by 61.2% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 20,295 shares of the company's stock after selling 32,022 shares during the period. Berkeley Inc's holdings in Zoetis were worth $2,554,000 at the
Zoetis (ZTS) concluded the recent trading session at $119.04, signifying a -1.42% move from its prior day's close.
Zoetis has strong growth prospects and an attractive income program. BioNTech has a rich pipeline that could help jolt the stock as it makes clinical progress.
One of Wall Street's top firms just gave a thumbs-up to Zoetis (NYSE:ZTS) stock.
Choreo LLC reduced its position in shares of Zoetis Inc. (NYSE: ZTS) by 30.6% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 15,049 shares of the company's stock after selling 6,637 shares during the quarter. Choreo LLC's holdings in Zoetis
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.